Sirtuin Inhibitor

SIRT1-IN-2 (compound 3h) is a potent and selective SIRT1 (silent information regulator 1) inhibitor, with an IC₅₀ of 1.6 μM.

SIRT5 inhibitor 7 (compound 58) is a substrate-competitive and selective SIRT5 inhibitor with anti-inflammatory activity. SIRT5 inhibitor 7 has renal protective effects and regulates protein succinylation and the release of pro-inflammatory cytokines. SIRT5 inhibitor 7 has in vivo activity in AKI mouse models of lipopolysaccharide (LPS) and cecal ligation/perforation (CLP)-induced sepsis-related acute kidney injury.

SIRT1-IN-3 (compound 3j) is a potent and selective SIRT1 inhibitor, with an IC₅₀ of 4.2 μM.

JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC₅₀ of ∼15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC₅₀>100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis with modulation of Bax/Bcl2 ratio, cytochrome c release and PARP cleavage. JGB1741 has the potential for breast cancer research.

Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin is a potent inhibitor of sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM). Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM). Suramin is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor.Suramin efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.

SIRT5 inhibitor 4 (compound 11) is a potent, selective SIRT5 inhibitor with IC₅₀ values of 26.4 and >400μM for SIRT5 and other SIRT subtype, respectively.

MI-217 is a potent SIRT3 inhibitor. MI-217 induces MDA-MB-231 apoptosis. MI-217 can be used in the study of breast cancer.

Sirt7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sirt7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

SIRT7 Human Pre-designed siRNA Set A contains three designed siRNAs for SIRT7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sirtuin-1 inhibitor 1 (Compound 8) is an inhibitor of Sirtuin-1 that plays important roles in obesity-induced diabetes and aging-related diseases.

Selisistat (Standard) is the analytical standard of Selisistat. This product is intended for research and analytical applications. Selisistat (EX-527) is a potent and selective SirT1 (Sir2 in Drosophila melanogaster) inhibitor with an IC50 of 123 nM for SirT1. Selisistat alleviates pathology in multiple animal and cell models of Huntington's disease.

Sirt1/2-IN-2 (compound hsa55) is a dual inhibitor of SIRT1/2 with IC₅₀s of 1.8 μM (SIRT1) and 2.4 μM (SIRT2), respsectivley. Sirt1/2-IN-2 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-2 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines.

SIRT2-IN-11 (AEM1) is a selective SIRT2 inhibitor with an IC₅₀ value of 18.5 μM. SIRT2-IN-11 p53-dependently induces apoptosis, activates expression of CDKN1A, PUMA and NOXA, and increases acetylation of p53. SIRT2-IN-11 can be used for the research of p53-related cancers.

AC-93253 is a selective, potent SIRT2 inhibitor. AC93253 can inhibit SIRT2 with an IC₅₀ value of 6 μM. AC93253 can be used for the research of tumors.

MIND4-19 is a potent SIRT2 inhibitor with an IC₅₀ value of 7.0 μM. MIND4-19 can be used for researching Huntington's disease.

Nicotinamide-¹⁵N,¹³C₃ is the ¹³C-labeled and ¹⁵N-labeled Nicotinamide. Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1.

Sirt3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sirt3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nicotinamide-¹³C,¹⁵N (Niacinamide-¹³C,¹⁵N) is the ¹³C- and ¹⁵N-labeled Nicotinamide (HY-B0150). Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity.

SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC₅₀ value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer.

Z26395438 (compound 1) is a potent Sirtuin-1 inhibitor, with an IC₅₀ value of 1.6 μM.